{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:22:58Z","timestamp":1793845378942,"version":"4.6.1"},"reference-count":330,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41573-024-01125-w","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T10:56:01Z","timestamp":1738061761000},"page":"335-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["FGF-based drug discovery: advances and challenges"],"prefix":"10.1038","volume":"24","author":[{"given":"Gaozhi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0089-6559","authenticated-orcid":false,"given":"Lingfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-6262","authenticated-orcid":false,"given":"Xiaokun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-9437","authenticated-orcid":false,"given":"Moosa","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"1125_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/jb\/mvq121","volume":"149","author":"N Itoh","year":"2011","unstructured":"Itoh, N. & Ornitz, D. M. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem. 149, 121\u2013130 (2011).","journal-title":"J. Biochem."},{"key":"1125_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd2792","volume":"8","author":"A Beenken","year":"2009","unstructured":"Beenken, A. & Mohammadi, M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug. Discov. 8, 235\u2013253 (2009).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1125_CR3","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/S0140-6736(98)01260-4","volume":"352","author":"X Fu","year":"1998","unstructured":"Fu, X. et al. Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns. Lancet 352, 1661\u20131664 (1998).","journal-title":"Lancet"},{"key":"1125_CR4","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1056\/NEJMoa040125","volume":"351","author":"R Spielberger","year":"2004","unstructured":"Spielberger, R. et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 351, 2590\u20132598 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I Urakawa","year":"2006","unstructured":"Urakawa, I. et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770\u2013774 (2006).","journal-title":"Nature"},{"key":"1125_CR6","doi-asserted-by":"publisher","first-page":"26687","DOI":"10.1074\/jbc.M704165200","volume":"282","author":"H Kurosu","year":"2007","unstructured":"Kurosu, H. et al. Tissue-specific expression of \u03b2Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687\u201326695 (2007).","journal-title":"J. Biol. Chem."},{"key":"1125_CR7","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.3390\/cells10092418","volume":"10","author":"P Phan","year":"2021","unstructured":"Phan, P. et al. The saga of endocrine FGFs. Cells 10, 2418 (2021).","journal-title":"Cells"},{"key":"1125_CR8","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba, R. et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N. Engl. J. Med. 389, 998\u20131008 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1053\/j.gastro.2023.04.007","volume":"165","author":"J BouSaba","year":"2023","unstructured":"BouSaba, J. et al. Effects of FGF19 analogue aldafermin in patients with bile acid diarrhea: a randomized, placebo-control trial. Gastroenterology 165, 499\u2013501.e494 (2023).","journal-title":"Gastroenterology"},{"key":"1125_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb, Y. N. Burosumab: first global approval. Drugs 78, 707\u2013714 (2018).","journal-title":"Drugs"},{"key":"1125_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature10998","volume":"485","author":"JW Jonker","year":"2012","unstructured":"Jonker, J. W. et al. A PPAR\u03b3-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485, 391\u2013394 (2012).","journal-title":"Nature"},{"key":"1125_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7980","volume":"6","author":"RJ Perry","year":"2015","unstructured":"Perry, R. J. et al. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat. Commun. 6, 6980 (2015).","journal-title":"Nat. Commun."},{"key":"1125_CR13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cmet.2023.04.018","volume":"35","author":"H Sun","year":"2023","unstructured":"Sun, H. et al. Sustained remission of type 2 diabetes in rodents by centrally administered fibroblast growth factor 4. Cell Metab. 35, 1022\u20131037.e1026 (2023).","journal-title":"Cell Metab."},{"key":"1125_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15055-9","volume":"11","author":"F Shamsi","year":"2020","unstructured":"Shamsi, F. et al. FGF6 and FGF9 regulate UCP1 expression independent of brown adipogenesis. Nat. Commun. 11, 1421 (2020).","journal-title":"Nat. Commun."},{"key":"1125_CR15","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1074\/jbc.M116.751404","volume":"292","author":"IC Rulifson","year":"2017","unstructured":"Rulifson, I. C. et al. In vitro and in vivo analyses reveal profound effects of ibroblast growth factor 16 as a metabolic regulator. J. Biol. Chem. 292, 1951\u20131969 (2017).","journal-title":"J. Biol. Chem."},{"key":"1125_CR16","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/nm.4101","volume":"22","author":"JM Scarlett","year":"2016","unstructured":"Scarlett, J. M. et al. Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents. Nat. Med. 22, 800\u2013806 (2016).","journal-title":"Nat. Med."},{"key":"1125_CR17","doi-asserted-by":"publisher","unstructured":"Zinkle, A. & Mohammadi, M. A threshold model for receptor tyrosine kinase signaling specificity and cell fate determination. F1000Res https:\/\/doi.org\/10.12688\/f1000research.14143.1 (2018).","DOI":"10.12688\/f1000research.14143.1"},{"key":"1125_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41586-023-06155-9","volume":"618","author":"L Chen","year":"2023","unstructured":"Chen, L. et al. Structural basis for FGF hormone signalling. Nature 618, 862\u2013870 (2023).","journal-title":"Nature"},{"key":"1125_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1549","volume":"14","author":"DM Ornitz","year":"2022","unstructured":"Ornitz, D. M. & Itoh, N. New developments in the biology of fibroblast growth factors. WIREs Mech. Dis. 14, e1549 (2022).","journal-title":"WIREs Mech. Dis."},{"key":"1125_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"DM Ornitz","year":"2015","unstructured":"Ornitz, D. M. & Itoh, N. The fibroblast growth factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 4, 215\u2013266 (2015).","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"1125_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie, Y. et al. FGF\/FGFR signaling in health and disease. Signal. Transduct. Target. Ther. 5, 181 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1125_CR22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s42255-022-00580-2","volume":"4","author":"E Gasser","year":"2022","unstructured":"Gasser, E., Sancar, G., Downes, M. & Evans, R. M. Metabolic messengers: fibroblast growth factor 1. Nat. Metab. 4, 663\u2013671 (2022).","journal-title":"Nat. Metab."},{"key":"1125_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-pharmtox-032322-093904","volume":"63","author":"L Jin","year":"2023","unstructured":"Jin, L., Yang, R., Geng, L. & Xu, A. Fibroblast growth factor-based pharmacotherapies for the treatment of obesity-related metabolic complications. Annu. Rev. Pharmacol. Toxicol. 63, 359\u2013382 (2023).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"1125_CR24","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","volume":"21","author":"M Katoh","year":"2024","unstructured":"Katoh, M. et al. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. Nat. Rev. Clin. Oncol. 21, 312\u2013329 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1125_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina, I. S. & Turner, N. C. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 17, 318\u2013332 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1125_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/bs.ctdb.2018.11.020","volume":"133","author":"DM Ornitz","year":"2019","unstructured":"Ornitz, D. M. & Marie, P. J. Fibroblast growth factors in skeletal development. Curr. Top. Dev. Biol. 133, 195\u2013234 (2019).","journal-title":"Curr. Top. Dev. Biol."},{"key":"1125_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.tig.2004.08.007","volume":"20","author":"N Itoh","year":"2004","unstructured":"Itoh, N. & Ornitz, D. M. Evolution of the Fgf and Fgfr gene families. Trends Genet. 20, 563\u2013569 (2004).","journal-title":"Trends Genet."},{"key":"1125_CR28","doi-asserted-by":"publisher","first-page":"a015958","DOI":"10.1101\/cshperspect.a015958","volume":"5","author":"AA Belov","year":"2013","unstructured":"Belov, A. A. & Mohammadi, M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb. Perspect. Biol. 5, a015958 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1125_CR29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S1097-2765(00)00073-3","volume":"6","author":"J Schlessinger","year":"2000","unstructured":"Schlessinger, J. et al. Crystal structure of a ternary FGF\u2013FGFR\u2013heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6, 743\u2013750 (2000).","journal-title":"Mol. Cell"},{"key":"1125_CR30","doi-asserted-by":"publisher","first-page":"100121","DOI":"10.1016\/j.mbplus.2022.100121","volume":"16","author":"D Pretorius","year":"2022","unstructured":"Pretorius, D., Richter, R. P., Anand, T., Cardenas, J. C. & Richter, J. R. Alterations in heparan sulfate proteoglycan synthesis and sulfation and the impact on vascular endothelial function. Matrix Biol. 16, 100121 (2022).","journal-title":"Matrix Biol."},{"key":"1125_CR31","doi-asserted-by":"crossref","unstructured":"Sarrazin, S., Lamanna, W. C. & Esko, J. D. Heparan sulfate proteoglycans. Cold Spring Harb. Perspect. Biol. 3, a004952 (2011).","DOI":"10.1101\/cshperspect.a004952"},{"key":"1125_CR32","doi-asserted-by":"publisher","first-page":"ra55","DOI":"10.1126\/scisignal.2000304","volume":"2","author":"HP Makarenkova","year":"2009","unstructured":"Makarenkova, H. P. et al. Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis. Sci. Signal. 2, ra55 (2009).","journal-title":"Sci. Signal."},{"key":"1125_CR33","doi-asserted-by":"publisher","first-page":"40061","DOI":"10.1074\/jbc.M112.398826","volume":"287","author":"R Xu","year":"2012","unstructured":"Xu, R. et al. Diversification of the structural determinants of fibroblast growth factor\u2013heparin interactions: implications for binding specificity. J. Biol. Chem. 287, 40061\u201340073 (2012).","journal-title":"J. Biol. Chem."},{"key":"1125_CR34","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1210\/en.2005-0670","volume":"146","author":"X Yu","year":"2005","unstructured":"Yu, X. et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146, 4647\u20134656 (2005).","journal-title":"Endocrinology"},{"key":"1125_CR35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3389\/fendo.2015.00154","volume":"6","author":"N Itoh","year":"2015","unstructured":"Itoh, N., Ohta, H. & Konishi, M. Endocrine FGFs: evolution, physiology, pathophysiology, and pharmacotherapy. Front. Endocrinol. 6, 154 (2015).","journal-title":"Front. Endocrinol."},{"key":"1125_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","volume":"61","author":"C Bergwitz","year":"2010","unstructured":"Bergwitz, C. & J\u00fcppner, H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu. Rev. Med. 61, 91\u2013104 (2010).","journal-title":"Annu. Rev. Med."},{"key":"1125_CR37","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1172\/JCI200319687","volume":"112","author":"LD Quarles","year":"2003","unstructured":"Quarles, L. D. Evidence for a bone-kidney axis regulating phosphate homeostasis. J. Clin. Invest. 112, 642\u2013646 (2003).","journal-title":"J. Clin. Invest."},{"key":"1125_CR38","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature25010","volume":"553","author":"S Lee","year":"2018","unstructured":"Lee, S. et al. Structures of \u03b2-Klotho reveal a \u2018zip code\u2019-like mechanism for endocrine FGF signalling. Nature 553, 501\u2013505 (2018).","journal-title":"Nature"},{"key":"1125_CR39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature25451","volume":"553","author":"G Chen","year":"2018","unstructured":"Chen, G. et al. \u03b1-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553, 461\u2013466 (2018).","journal-title":"Nature"},{"key":"1125_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1073\/pnas.97.1.49","volume":"97","author":"DJ Stauber","year":"2000","unstructured":"Stauber, D. J., DiGabriele, A. D. & Hendrickson, W. A. Structural interactions of fibroblast growth factor receptor with its ligands. Proc. Natl Acad. Sci. USA 97, 49\u201354 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0092-8674(00)80051-3","volume":"98","author":"AN Plotnikov","year":"1999","unstructured":"Plotnikov, A. N., Schlessinger, J., Hubbard, S. R. & Mohammadi, M. Structural basis for FGF receptor dimerization and activation. Cell 98, 641\u2013650 (1999).","journal-title":"Cell"},{"key":"1125_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.str.2011.10.022","volume":"20","author":"J Kalinina","year":"2012","unstructured":"Kalinina, J. et al. The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition. Structure 20, 77\u201388 (2012).","journal-title":"Structure"},{"key":"1125_CR43","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1073\/pnas.0307287101","volume":"101","author":"SK Olsen","year":"2004","unstructured":"Olsen, S. K. et al. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc. Natl Acad. Sci. USA 101, 935\u2013940 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR44","doi-asserted-by":"publisher","first-page":"15694","DOI":"10.1074\/jbc.M601252200","volume":"281","author":"X Zhang","year":"2006","unstructured":"Zhang, X. et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 281, 15694\u201315700 (2006).","journal-title":"J. Biol. Chem."},{"key":"1125_CR45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41589-019-0455-7","volume":"16","author":"L Chen","year":"2020","unstructured":"Chen, L. et al. Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation. Nat. Chem. Biol. 16, 267\u2013277 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"1125_CR46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.molcel.2015.11.010","volume":"61","author":"Z Huang","year":"2016","unstructured":"Huang, Z. et al. Two FGF receptor kinase molecules act in concert to recruit and transphosphorylate phospholipase C\u03b3. Mol. Cell 61, 98\u2013110 (2016).","journal-title":"Mol. Cell"},{"key":"1125_CR47","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1073\/pnas.94.7.2999","volume":"94","author":"QS Ji","year":"1997","unstructured":"Ji, Q. S. et al. Essential role of the tyrosine kinase substrate phospholipase C-\u03b31 in mammalian growth and development. Proc. Natl Acad. Sci. USA 94, 2999\u20133003 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR48","doi-asserted-by":"publisher","first-page":"11650","DOI":"10.1074\/jbc.273.19.11650","volume":"273","author":"MV Ellis","year":"1998","unstructured":"Ellis, M. V. et al. Catalytic domain of phosphoinositide-specific phospholipase C (PLC). Mutational analysis of residues within the active site and hydrophobic ridge of PLC\u03b41. J. Biol. Chem. 273, 11650\u201311659 (1998).","journal-title":"J. Biol. Chem."},{"key":"1125_CR49","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1128\/MCB.20.3.979-989.2000","volume":"20","author":"SH Ong","year":"2000","unstructured":"Ong, S. H. et al. FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol. Cell Biol. 20, 979\u2013989 (2000).","journal-title":"Mol. Cell Biol."},{"key":"1125_CR50","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S1097-2765(05)00087-0","volume":"6","author":"C Dhalluin","year":"2000","unstructured":"Dhalluin, C. et al. Structural basis of SNT PTB domain interactions with distinct neurotrophic receptors. Mol. Cell 6, 921\u2013929 (2000).","journal-title":"Mol. Cell"},{"key":"1125_CR51","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/sj.onc.1204290","volume":"20","author":"K Kurokawa","year":"2001","unstructured":"Kurokawa, K. et al. Identification of SNT\/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction. Oncogene 20, 1929\u20131938 (2001).","journal-title":"Oncogene"},{"key":"1125_CR52","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","volume":"16","author":"VP Eswarakumar","year":"2005","unstructured":"Eswarakumar, V. P., Lax, I. & Schlessinger, J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor. Rev. 16, 139\u2013149 (2005).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"1125_CR53","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/cells8050455","volume":"8","author":"M Latko","year":"2019","unstructured":"Latko, M. et al. Cross-talk between fibroblast growth factor receptors and other cell surface proteins. Cells 8, 455 (2019).","journal-title":"Cells"},{"key":"1125_CR54","first-page":"721","volume":"13","author":"JK Wang","year":"1996","unstructured":"Wang, J. K., Xu, H., Li, H. C. & Goldfarb, M. Broadly expressed SNT-like proteins link FGF receptor stimulation to activators of Ras. Oncogene 13, 721\u2013729 (1996).","journal-title":"Oncogene"},{"key":"1125_CR55","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0092-8674(00)80252-4","volume":"89","author":"H Kouhara","year":"1997","unstructured":"Kouhara, H. et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras\/MAPK signaling pathway. Cell 89, 693\u2013702 (1997).","journal-title":"Cell"},{"key":"1125_CR56","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1128\/MCB.18.7.3966","volume":"18","author":"YR Hadari","year":"1998","unstructured":"Hadari, Y. R., Kouhara, H., Lax, I. & Schlessinger, J. Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol. Cell Biol. 18, 3966\u20133973 (1998).","journal-title":"Mol. Cell Biol."},{"key":"1125_CR57","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1073\/pnas.111114298","volume":"98","author":"SH Ong","year":"2001","unstructured":"Ong, S. H. et al. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc. Natl Acad. Sci. USA 98, 6074\u20136079 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR58","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.32586","volume":"7","author":"TN Collins","year":"2018","unstructured":"Collins, T. N. et al. Crk proteins transduce FGF signaling to promote lens fiber cell elongation. Elife 7, e32586 (2018).","journal-title":"Elife"},{"key":"1125_CR59","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1038\/sj.onc.1203027","volume":"18","author":"JF Liu","year":"1999","unstructured":"Liu, J. F. et al. Functional Rac-1 and Nck signaling networks are required for FGF-2-induced DNA synthesis in MCF-7 cells. Oncogene 18, 6425\u20136433 (1999).","journal-title":"Oncogene"},{"key":"1125_CR60","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/j.1349-7006.2008.00840.x","volume":"99","author":"N Gotoh","year":"2008","unstructured":"Gotoh, N. Regulation of growth factor signaling by FRS2 family docking\/scaffold adaptor proteins. Cancer Sci. 99, 1319\u20131325 (2008).","journal-title":"Cancer Sci."},{"key":"1125_CR61","doi-asserted-by":"publisher","first-page":"10384","DOI":"10.1523\/JNEUROSCI.3400-04.2004","volume":"24","author":"D Gonz\u00e1lez-Mart\u00ednez","year":"2004","unstructured":"Gonz\u00e1lez-Mart\u00ednez, D. et al. Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism. J. Neurosci. 24, 10384\u201310392 (2004).","journal-title":"J. Neurosci."},{"key":"1125_CR62","doi-asserted-by":"publisher","first-page":"31103","DOI":"10.1074\/jbc.M704430200","volume":"282","author":"Y Zhang","year":"2007","unstructured":"Zhang, Y. et al. Regulation of ephexin1, a guanine nucleotide exchange factor of Rho family GTPases, by fibroblast growth factor receptor-mediated tyrosine phosphorylation. J. Biol. Chem. 282, 31103\u201331112 (2007).","journal-title":"J. Biol. Chem."},{"key":"1125_CR63","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1083\/jcb.149.6.1297","volume":"149","author":"A Mansukhani","year":"2000","unstructured":"Mansukhani, A., Bellosta, P., Sahni, M. & Basilico, C. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J. Cell Biol. 149, 1297\u20131308 (2000).","journal-title":"J. Cell Biol."},{"key":"1125_CR64","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/j.1471-4159.2006.03789.x","volume":"97","author":"JB Easton","year":"2006","unstructured":"Easton, J. B., Royer, A. R. & Middlemas, D. S. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS\/MAPK pathway by brain-derived neurotrophic factor. J. Neurochem. 97, 834\u2013845 (2006).","journal-title":"J. Neurochem."},{"key":"1125_CR65","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1158\/0008-5472.CAN-09-3033","volume":"70","author":"AA Dudka","year":"2010","unstructured":"Dudka, A. A., Sweet, S. M. & Heath, J. K. Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification. Cancer Res. 70, 3391\u20133401 (2010).","journal-title":"Cancer Res."},{"key":"1125_CR66","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1053\/j.gastro.2022.05.016","volume":"163","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Induction of fibroblast growth factor receptor 4 by Helicobacter pylori via signal transducer and activator of transcription 3 with a feedforward activation loop involving SRC signaling in gastric cancer. Gastroenterology 163, 620\u2013636.e629 (2022).","journal-title":"Gastroenterology"},{"key":"1125_CR67","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.4049\/jimmunol.1801199","volume":"202","author":"P Li","year":"2019","unstructured":"Li, P. et al. FGFR2 promotes expression of PD-L1 in colorectal cancer via the JAK\/STAT3 signaling pathway. J. Immunol. 202, 3065\u20133075 (2019).","journal-title":"J. Immunol."},{"key":"1125_CR68","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature16449","volume":"528","author":"VK Ulaganathan","year":"2015","unstructured":"Ulaganathan, V. K., Sperl, B., Rapp, U. R. & Ullrich, A. Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site. Nature 528, 570\u2013574 (2015).","journal-title":"Nature"},{"key":"1125_CR69","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10637-021-01061-1","volume":"39","author":"X Song","year":"2021","unstructured":"Song, X., Tang, W., Peng, H., Qi, X. & Li, J. FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment. Invest. N. Drugs 39, 1201\u20131212 (2021).","journal-title":"Invest. N. Drugs"},{"key":"1125_CR70","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cellsig.2017.10.003","volume":"42","author":"L Balek","year":"2018","unstructured":"Balek, L. et al. Proteomic analyses of signalling complexes associated with receptor tyrosine kinase identify novel members of fibroblast growth factor receptor 3 interactome. Cell Signal. 42, 144\u2013154 (2018).","journal-title":"Cell Signal."},{"key":"1125_CR71","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1073\/pnas.1800338116","volume":"116","author":"M Kunova Bosakova","year":"2019","unstructured":"Kunova Bosakova, M. et al. Fibroblast growth factor receptor influences primary cilium length through an interaction with intestinal cell kinase. Proc. Natl Acad. Sci. USA 116, 4316\u20134325 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR72","doi-asserted-by":"crossref","unstructured":"Fafilek, B. et al. The inositol phosphatase SHIP2 enables sustained ERK activation downstream of FGF receptors by recruiting Src kinases. Sci. Signal. 11, eaap8608 (2018).","DOI":"10.1126\/scisignal.aap8608"},{"key":"1125_CR73","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1101\/gad.1365406","volume":"20","author":"SK Olsen","year":"2006","unstructured":"Olsen, S. K. et al. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev. 20, 185\u2013198 (2006).","journal-title":"Genes Dev."},{"key":"1125_CR74","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cmet.2016.09.001","volume":"24","author":"SM Solon-Biet","year":"2016","unstructured":"Solon-Biet, S. M. et al. Defining the nutritional and metabolic context of FGF21 using the geometric framework. Cell Metab. 24, 555\u2013565 (2016).","journal-title":"Cell Metab."},{"key":"1125_CR75","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1172\/JCI74915","volume":"124","author":"T Laeger","year":"2014","unstructured":"Laeger, T. et al. FGF21 is an endocrine signal of protein restriction. J. Clin. Invest. 124, 3913\u20133922 (2014).","journal-title":"J. Clin. Invest."},{"key":"1125_CR76","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.2337\/db14-0595","volume":"63","author":"KR Markan","year":"2014","unstructured":"Markan, K. R. et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63, 4057\u20134063 (2014).","journal-title":"Diabetes"},{"key":"1125_CR77","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.1172\/JCI83349","volume":"125","author":"PK Fazeli","year":"2015","unstructured":"Fazeli, P. K. et al. FGF21 and the late adaptive response to starvation in humans. J. Clin. Invest. 125, 4601\u20134611 (2015).","journal-title":"J. Clin. Invest."},{"key":"1125_CR78","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.cmet.2014.06.010","volume":"20","author":"S Vernia","year":"2014","unstructured":"Vernia, S. et al. The PPAR\u03b1-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway. Cell Metab. 20, 512\u2013525 (2014).","journal-title":"Cell Metab."},{"key":"1125_CR79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2210434119","volume":"119","author":"S Vernia","year":"2022","unstructured":"Vernia, S. et al. Phosphorylation of RXR\u03b1 mediates the effect of JNK to suppress hepatic FGF21 expression and promote metabolic syndrome. Proc. Natl Acad. Sci. USA 119, e2210434119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR80","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.2337\/db14-0541","volume":"63","author":"Q Liang","year":"2014","unstructured":"Liang, Q. et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 63, 4064\u20134075 (2014).","journal-title":"Diabetes"},{"key":"1125_CR81","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.1074\/jbc.M116.762922","volume":"292","author":"KM Alonge","year":"2017","unstructured":"Alonge, K. M., Meares, G. P. & Hillgartner, F. B. Glucagon and insulin cooperatively stimulate fibroblast growth factor 21 gene transcription by increasing the expression of activating transcription factor 4. J. Biol. Chem. 292, 5239\u20135252 (2017).","journal-title":"J. Biol. Chem."},{"key":"1125_CR82","doi-asserted-by":"publisher","first-page":"29751","DOI":"10.1074\/jbc.M114.565960","volume":"289","author":"S Jiang","year":"2014","unstructured":"Jiang, S. et al. Fibroblast growth factor 21 is regulated by the IRE1\u03b1-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J. Biol. Chem. 289, 29751\u201329765 (2014).","journal-title":"J. Biol. Chem."},{"key":"1125_CR83","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.15252\/embj.201696179","volume":"36","author":"RO Pereira","year":"2017","unstructured":"Pereira, R. O. et al. OPA1 deficiency promotes secretion of FGF21 from muscle that prevents obesity and insulin resistance. EMBO J. 36, 2126\u20132145 (2017).","journal-title":"EMBO J."},{"key":"1125_CR84","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cell.2011.11.062","volume":"148","author":"PA Dutchak","year":"2012","unstructured":"Dutchak, P. A. et al. Fibroblast growth factor-21 regulates PPAR\u03b3 activity and the antidiabetic actions of thiazolidinediones. Cell 148, 556\u2013567 (2012).","journal-title":"Cell"},{"key":"1125_CR85","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.28523","volume":"64","author":"Q Gong","year":"2016","unstructured":"Gong, Q. et al. Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice. Hepatology 64, 425\u2013438 (2016).","journal-title":"Hepatology"},{"key":"1125_CR86","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1111\/febs.12767","volume":"281","author":"C Wang","year":"2014","unstructured":"Wang, C. et al. Silencing of FGF-21 expression promotes hepatic gluconeogenesis and glycogenolysis by regulation of the STAT3\u2013SOCS3 signal. FEBS J. 281, 2136\u20132147 (2014).","journal-title":"FEBS J."},{"key":"1125_CR87","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.cmet.2019.08.004","volume":"30","author":"S Geller","year":"2019","unstructured":"Geller, S. et al. Tanycytes regulate lipid homeostasis by sensing free fatty acids and signaling to key hypothalamic neuronal populations via FGF21 secretion. Cell Metab. 30, 833\u2013844.e837 (2019).","journal-title":"Cell Metab."},{"key":"1125_CR88","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s42255-022-00602-z","volume":"4","author":"V Pena-Leon","year":"2022","unstructured":"Pena-Leon, V. et al. Prolonged breastfeeding protects from obesity by hypothalamic action of hepatic FGF21. Nat. Metab. 4, 901\u2013917 (2022).","journal-title":"Nat. Metab."},{"key":"1125_CR89","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2337\/db09-1878","volume":"59","author":"DA Sarruf","year":"2010","unstructured":"Sarruf, D. A. et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59, 1817\u20131824 (2010).","journal-title":"Diabetes"},{"key":"1125_CR90","first-page":"603","volume":"31","author":"L Recinella","year":"2017","unstructured":"Recinella, L. et al. Effects of central fibroblast growth factor 21 (FGF21) in energy balance. J. Biol. Regul. Homeost. Agents 31, 603\u2013613 (2017).","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"1125_CR91","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cmet.2014.07.012","volume":"20","author":"BM Owen","year":"2014","unstructured":"Owen, B. M. et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 20, 670\u2013677 (2014).","journal-title":"Cell Metab."},{"key":"1125_CR92","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.cmet.2013.12.017","volume":"19","author":"P Lee","year":"2014","unstructured":"Lee, P. et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab. 19, 302\u2013309 (2014).","journal-title":"Cell Metab."},{"key":"1125_CR93","doi-asserted-by":"publisher","first-page":"109331","DOI":"10.1016\/j.celrep.2021.109331","volume":"35","author":"M Abu-Odeh","year":"2021","unstructured":"Abu-Odeh, M. et al. FGF21 promotes thermogenic gene expression as an autocrine factor in adipocytes. Cell Rep. 35, 109331 (2021).","journal-title":"Cell Rep."},{"key":"1125_CR94","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.cmet.2016.08.003","volume":"24","author":"L Lynch","year":"2016","unstructured":"Lynch, L. et al. iNKT cells induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy. Cell Metab. 24, 510\u2013519 (2016).","journal-title":"Cell Metab."},{"key":"1125_CR95","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1126\/science.abi9547","volume":"377","author":"AL Cangelosi","year":"2022","unstructured":"Cangelosi, A. L. et al. Zonated leucine sensing by Sestrin-mTORC1 in the liver controls the response to dietary leucine. Science 377, 47\u201356 (2022).","journal-title":"Science"},{"key":"1125_CR96","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145546","volume":"131","author":"SM Reilly","year":"2021","unstructured":"Reilly, S. M. et al. FGF21 is required for the metabolic benefits of IKK\u03b5\/TBK1 inhibition. J. Clin. Invest. 131, e145546 (2021).","journal-title":"J. Clin. Invest."},{"key":"1125_CR97","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1101\/gad.177857.111","volume":"26","author":"FM Fisher","year":"2012","unstructured":"Fisher, F. M. et al. FGF21 regulates PGC-1\u03b1 and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26, 271\u2013281 (2012).","journal-title":"Genes Dev."},{"key":"1125_CR98","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cmet.2017.08.003","volume":"26","author":"Z Huang","year":"2017","unstructured":"Huang, Z. et al. The FGF21\u2013CCL11 axis mediates beiging of white adipose tissues by coupling sympathetic nervous system to type 2 immunity. Cell Metab. 26, 493\u2013508.e494 (2017).","journal-title":"Cell Metab."},{"key":"1125_CR99","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.cmet.2018.04.002","volume":"27","author":"X Pan","year":"2018","unstructured":"Pan, X. et al. FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2\/angiotensin-(1\u20137) axis in mice. Cell Metab. 27, 1323\u20131337.e1325 (2018).","journal-title":"Cell Metab."},{"key":"1125_CR100","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1111\/jphp.12826","volume":"69","author":"F Cao","year":"2017","unstructured":"Cao, F. et al. Fibroblast growth factor 21 attenuates calcification of vascular smooth muscle cells in vitro. J. Pharm. Pharmacol. 69, 1802\u20131816 (2017).","journal-title":"J. Pharm. Pharmacol."},{"key":"1125_CR101","doi-asserted-by":"publisher","first-page":"138","DOI":"10.7150\/ijbs.28873","volume":"15","author":"Y Shi","year":"2019","unstructured":"Shi, Y. et al. Fibroblast growth factor 21 attenuates vascular calcification by alleviating endoplasmic reticulum stress mediated apoptosis in rats. Int. J. Biol. Sci. 15, 138\u2013147 (2019).","journal-title":"Int. J. Biol. Sci."},{"key":"1125_CR102","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1016\/j.bbrc.2017.10.115","volume":"495","author":"Y Shi","year":"2018","unstructured":"Shi, Y. et al. Fibroblast growth factor 21 ameliorates vascular calcification by inhibiting osteogenic transition in vitamin D3 plus nicotine-treated rats. Biochem. Biophys. Res. Commun. 495, 2448\u20132455 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1125_CR103","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1161\/CIRCULATIONAHA.115.015308","volume":"131","author":"Z Lin","year":"2015","unstructured":"Lin, Z. et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation 131, 1861\u20131871 (2015).","journal-title":"Circulation"},{"key":"1125_CR104","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.122.059631","volume":"146","author":"L Jin","year":"2022","unstructured":"Jin, L. et al. FGF21\u2013Sirtuin 3 axis confers the protective effects of exercise against diabetic cardiomyopathy by governing mitochondrial integrity. Circulation 146, 1537\u20131557 (2022).","journal-title":"Circulation"},{"key":"1125_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05842-9","volume":"14","author":"B Yan","year":"2023","unstructured":"Yan, B. et al. FGF21\u2013FGFR1 controls mitochondrial homeostasis in cardiomyocytes by modulating the degradation of OPA1. Cell Death Dis. 14, 311 (2023).","journal-title":"Cell Death Dis."},{"key":"1125_CR106","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/cvr\/cvu263","volume":"106","author":"A Planavila","year":"2015","unstructured":"Planavila, A. et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc. Res. 106, 19\u201331 (2015).","journal-title":"Cardiovasc. Res."},{"key":"1125_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3019","volume":"4","author":"A Planavila","year":"2013","unstructured":"Planavila, A. et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat. Commun. 4, 2019 (2013).","journal-title":"Nat. Commun."},{"key":"1125_CR108","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cmet.2020.06.008","volume":"32","author":"SO Jensen-Cody","year":"2020","unstructured":"Jensen-Cody, S. O. et al. FGF21 signals to glutamatergic neurons in the ventromedial hypothalamus to suppress carbohydrate intake. Cell Metab. 32, 273\u2013286.e276 (2020).","journal-title":"Cell Metab."},{"key":"1125_CR109","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.cmet.2015.12.003","volume":"23","author":"S von Holstein-Rathlou","year":"2016","unstructured":"von Holstein-Rathlou, S. et al. FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver. Cell Metab. 23, 335\u2013343 (2016).","journal-title":"Cell Metab."},{"key":"1125_CR110","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.cmet.2017.04.009","volume":"25","author":"S S\u00f8berg","year":"2017","unstructured":"S\u00f8berg, S. et al. FGF21 is a sugar-induced hormone associated with sweet intake and preference in humans. Cell Metab. 25, 1045\u20131053.e1046 (2017).","journal-title":"Cell Metab."},{"key":"1125_CR111","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cmet.2015.12.008","volume":"23","author":"S Talukdar","year":"2016","unstructured":"Talukdar, S. et al. FGF21 regulates sweet and alcohol preference. Cell Metab. 23, 344\u2013349 (2016).","journal-title":"Cell Metab."},{"key":"1125_CR112","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1016\/j.celrep.2019.05.022","volume":"27","author":"CM Hill","year":"2019","unstructured":"Hill, C. M. et al. FGF21 signals protein status to the brain and adaptively regulates food choice and metabolism. Cell Rep. 27, 2934\u20132947.e2933 (2019).","journal-title":"Cell Rep."},{"key":"1125_CR113","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cmet.2021.12.024","volume":"34","author":"KH Flippo","year":"2022","unstructured":"Flippo, K. H. et al. FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit. Cell Metab. 34, 317\u2013328.e316 (2022).","journal-title":"Cell Metab."},{"key":"1125_CR114","doi-asserted-by":"publisher","first-page":"14372","DOI":"10.1073\/pnas.1611243113","volume":"113","author":"G Schumann","year":"2016","unstructured":"Schumann, G. et al. KLB is associated with alcohol drinking, and its gene product \u03b2-Klotho is necessary for FGF21 regulation of alcohol preference. Proc. Natl Acad. Sci. USA 113, 14372\u201314377 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR115","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.cmet.2018.04.001","volume":"27","author":"P Song","year":"2018","unstructured":"Song, P. et al. The hormone FGF21 stimulates water drinking in response to ketogenic diet and alcohol. Cell Metab. 27, 1338\u20131347.e1334 (2018).","journal-title":"Cell Metab."},{"key":"1125_CR116","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cmet.2023.02.005","volume":"35","author":"M Choi","year":"2023","unstructured":"Choi, M. et al. FGF21 counteracts alcohol intoxication by activating the noradrenergic nervous system. Cell Metab. 35, 429\u2013437.e425 (2023).","journal-title":"Cell Metab."},{"key":"1125_CR117","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.molmet.2017.08.004","volume":"6","author":"BN Desai","year":"2017","unstructured":"Desai, B. N. et al. Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. Mol. Metab. 6, 1395\u20131406 (2017).","journal-title":"Mol. Metab."},{"key":"1125_CR118","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.cmet.2016.12.004","volume":"25","author":"KC Coate","year":"2017","unstructured":"Coate, K. C. et al. FGF21 is an exocrine pancreas secretagogue. Cell Metab. 25, 472\u2013480 (2017).","journal-title":"Cell Metab."},{"key":"1125_CR119","doi-asserted-by":"publisher","first-page":"eaay5186","DOI":"10.1126\/scitranslmed.aay5186","volume":"12","author":"G Hernandez","year":"2020","unstructured":"Hernandez, G. et al. Pancreatitis is an FGF21-deficient state that is corrected by replacement therapy. Sci. Transl. Med. 12, eaay5186 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1125_CR120","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00774-016-0745-z","volume":"35","author":"N Charoenphandhu","year":"2017","unstructured":"Charoenphandhu, N. et al. Fibroblast growth factor-21 restores insulin sensitivity but induces aberrant bone microstructure in obese insulin-resistant rats. J. Bone Min. Metab. 35, 142\u2013149 (2017).","journal-title":"J. Bone Min. Metab."},{"key":"1125_CR121","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1073\/pnas.1200797109","volume":"109","author":"W Wei","year":"2012","unstructured":"Wei, W. et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor \u03b3. Proc. Natl Acad. Sci. USA 109, 3143\u20133148 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR122","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cmet.2008.05.006","volume":"8","author":"T Inagaki","year":"2008","unstructured":"Inagaki, T. et al. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 8, 77\u201383 (2008).","journal-title":"Cell Metab."},{"key":"1125_CR123","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cmet.2015.09.010","volume":"22","author":"X Wang","year":"2015","unstructured":"Wang, X., Wei, W., Krzeszinski, J. Y., Wang, Y. & Wan, Y. A liver-bone endocrine relay by IGFBP1 promotes osteoclastogenesis and mediates FGF21-induced bone resorption. Cell Metab. 22, 811\u2013824 (2015).","journal-title":"Cell Metab."},{"key":"1125_CR124","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1210\/en.2014-1083","volume":"155","author":"S Bornstein","year":"2014","unstructured":"Bornstein, S. et al. FGF-21 and skeletal remodeling during and after lactation in C57BL\/6J mice. Endocrinology 155, 3516\u20133526 (2014).","journal-title":"Endocrinology"},{"key":"1125_CR125","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/jbmr.3932","volume":"35","author":"H Li","year":"2020","unstructured":"Li, H. et al. Increased expression of FGF-21 negatively affects bone homeostasis in dystrophin\/utrophin double knockout mice. J. Bone Min. Res. 35, 738\u2013752 (2020).","journal-title":"J. Bone Min. Res."},{"key":"1125_CR126","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","volume":"23","author":"S Talukdar","year":"2016","unstructured":"Talukdar, S. et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 23, 427\u2013440 (2016).","journal-title":"Cell Metab."},{"key":"1125_CR127","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1210\/clinem\/dgab624","volume":"107","author":"DJ Rader","year":"2022","unstructured":"Rader, D. J. et al. LLF580, an FGF21 analog, reduces triglycerides and hepatic fat in obese adults with modest hypertriglyceridemia. J. Clin. Endocrinol. Metab. 107, e57\u2013e70 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1125_CR128","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/jbmr.2936","volume":"32","author":"X Li","year":"2017","unstructured":"Li, X. et al. FGF21 is not a major mediator for bone homeostasis or metabolic actions of PPAR\u03b1 and PPAR\u03b3 agonists. J. Bone Min. Res. 32, 834\u2013845 (2017).","journal-title":"J. Bone Min. Res."},{"key":"1125_CR129","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708791","volume":"10","author":"V Jimenez","year":"2018","unstructured":"Jimenez, V. et al. FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol. Med. 10, e8791 (2018).","journal-title":"EMBO Mol. Med."},{"key":"1125_CR130","doi-asserted-by":"publisher","first-page":"115673","DOI":"10.1016\/j.taap.2021.115673","volume":"428","author":"KE Thompson","year":"2021","unstructured":"Thompson, K. E., Guillot, M., Graziano, M. J., Mangipudy, R. S. & Chadwick, K. D. Pegbelfermin, a PEGylated FGF21 analogue, has pharmacology without bone toxicity after 1-year dosing in skeletally-mature monkeys. Toxicol. Appl. Pharmacol. 428, 115673 (2021).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"1125_CR131","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3803\/EnM.2018.33.2.273","volume":"33","author":"HS Choi","year":"2018","unstructured":"Choi, H. S., Lee, H. A., Kim, S. W. & Cho, E. H. Association between serum fibroblast growth factor 21 levels and bone mineral density in postmenopausal women. Endocrinol. Metab. 33, 273\u2013277 (2018).","journal-title":"Endocrinol. Metab."},{"key":"1125_CR132","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1007\/s00198-013-2464-9","volume":"24","author":"P Lee","year":"2013","unstructured":"Lee, P. et al. Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans? Osteoporos. Int. 24, 3053\u20133057 (2013).","journal-title":"Osteoporos. Int."},{"key":"1125_CR133","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.cmet.2019.08.019","volume":"30","author":"S Forsstr\u00f6m","year":"2019","unstructured":"Forsstr\u00f6m, S. et al. Fibroblast growth factor 21 drives dynamics of local and systemic stress responses in mitochondrial myopathy with mtDNA deletions. Cell Metab. 30, 1040\u20131054.e1047 (2019).","journal-title":"Cell Metab."},{"key":"1125_CR134","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1210\/endrev\/bnad004","volume":"44","author":"NT Boardman","year":"2023","unstructured":"Boardman, N. T., Trani, G., Scalabrin, M., Romanello, V. & W\u00fcst, R. C. I. Intracellular to interorgan mitochondrial communication in striated muscle in health and disease. Endocr. Rev. 44, 668\u2013692 (2023).","journal-title":"Endocr. Rev."},{"key":"1125_CR135","doi-asserted-by":"publisher","first-page":"115877","DOI":"10.1016\/j.bone.2021.115877","volume":"145","author":"HW Jung","year":"2021","unstructured":"Jung, H. W. et al. Association between serum FGF21 level and sarcopenia in older adults. Bone 145, 115877 (2021).","journal-title":"Bone"},{"key":"1125_CR136","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov, A. et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627\u20131635 (2005).","journal-title":"J. Clin. Invest."},{"key":"1125_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4614-0887-1_1","volume":"728","author":"A Beenken","year":"2012","unstructured":"Beenken, A. & Mohammadi, M. The structural biology of the FGF19 subfamily. Adv. Exp. Med. Biol. 728, 1\u201324 (2012).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1125_CR138","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","volume":"16","author":"L Geng","year":"2020","unstructured":"Geng, L., Lam, K. S. L. & Xu, A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat. Rev. Endocrinol. 16, 654\u2013667 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1125_CR139","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.tem.2024.02.001","volume":"35","author":"ZSW Chui","year":"2024","unstructured":"Chui, Z. S. W., Shen, Q. & Xu, A. Current status and future perspectives of FGF21 analogues in clinical trials. Trends Endocrinol. Metab. 35, 371\u2013384 (2024).","journal-title":"Trends Endocrinol. Metab."},{"key":"1125_CR140","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","volume":"18","author":"G Gaich","year":"2013","unstructured":"Gaich, G. et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333\u2013340 (2013).","journal-title":"Cell Metab."},{"key":"1125_CR141","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cmet.2013.08.014","volume":"18","author":"ML Reitman","year":"2013","unstructured":"Reitman, M. L. FGF21 mimetic shows therapeutic promise. Cell Metab. 18, 307\u2013309 (2013).","journal-title":"Cell Metab."},{"key":"1125_CR142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058575","volume":"8","author":"A Kharitonenkov","year":"2013","unstructured":"Kharitonenkov, A. et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE 8, e58575 (2013).","journal-title":"PLoS ONE"},{"key":"1125_CR143","volume":"16","author":"KR Santhanakrishnan","year":"2024","unstructured":"Santhanakrishnan, K. R., Koilpillai, J. & Narayanasamy, D. PEGylation in pharmaceutical development: current status and emerging trends in macromolecular and immunotherapeutic drugs. Cureus 16, e66669 (2024).","journal-title":"Cureus"},{"key":"1125_CR144","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","volume":"392","author":"A Sanyal","year":"2019","unstructured":"Sanyal, A. et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 392, 2705\u20132717 (2019).","journal-title":"Lancet"},{"key":"1125_CR145","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2337\/db11-0838","volume":"61","author":"J Mu","year":"2012","unstructured":"Mu, J. et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61, 505\u2013512 (2012).","journal-title":"Diabetes"},{"key":"1125_CR146","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/13543784.2020.1708898","volume":"29","author":"CRC Verzijl","year":"2020","unstructured":"Verzijl, C. R. C., Van De Peppel, I. P., Struik, D. & Jonker, J. W. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis. Expert. Opin. Investig. Drugs 29, 125\u2013133 (2020).","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"1125_CR147","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","volume":"22","author":"R Loomba","year":"2024","unstructured":"Loomba, R. et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study. Clin. Gastroenterol. Hepatol. 22, 102\u2013112.e109 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1125_CR148","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","volume":"22","author":"MF Abdelmalek","year":"2024","unstructured":"Abdelmalek, M. F. et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study. Clin. Gastroenterol. Hepatol. 22, 113\u2013123.e119 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1125_CR149","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1124\/jpet.123.001618","volume":"387","author":"M Rosenstock","year":"2023","unstructured":"Rosenstock, M. et al. The novel GlycoPEGylated FGF21 analog pegozafermin activates human FGF receptors and improves metabolic and liver outcomes in diabetic monkeys and healthy human volunteers. J. Pharmacol. Exp. Ther. 387, 204\u2013213 (2023).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1125_CR150","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba, R. et al. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study. Lancet Gastroenterol. Hepatol. 8, 120\u2013132 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1125_CR151","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1124\/jpet.113.204420","volume":"346","author":"J Huang","year":"2013","unstructured":"Huang, J. et al. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J. Pharmacol. Exp. Ther. 346, 270\u2013280 (2013).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1125_CR152","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/bcp.12676","volume":"80","author":"JQ Dong","year":"2015","unstructured":"Dong, J. Q. et al. Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. Br. J. Clin. Pharmacol. 80, 1051\u20131063 (2015).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1125_CR153","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/13543784.2023.2230115","volume":"32","author":"T Puengel","year":"2023","unstructured":"Puengel, T. & Tacke, F. Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH). Expert. Opin. Investig. Drugs 32, 451\u2013461 (2023).","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"1125_CR154","doi-asserted-by":"publisher","first-page":"100057","DOI":"10.1016\/j.xcrm.2020.100057","volume":"1","author":"A Kaufman","year":"2020","unstructured":"Kaufman, A., Abuqayyas, L., Denney, W. S., Tillman, E. J. & Rolph, T. AKR-001, an Fc\u2013FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients. Cell Rep. Med. 1, 100057 (2020).","journal-title":"Cell Rep. Med."},{"key":"1125_CR155","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1210\/en.2016-1917","volume":"158","author":"S Stanislaus","year":"2017","unstructured":"Stanislaus, S. et al. A novel Fc\u2013FGF21 with improved resistance to proteolysis, increased affinity toward \u03b2-Klotho, and enhanced efficacy in mice and cynomolgus monkeys. Endocrinology 158, 1314\u20131327 (2017).","journal-title":"Endocrinology"},{"key":"1125_CR156","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1210\/en.2012-1211","volume":"153","author":"MM V\u00e9niant","year":"2012","unstructured":"V\u00e9niant, M. M. et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 153, 4192\u20134203 (2012).","journal-title":"Endocrinology"},{"key":"1125_CR157","doi-asserted-by":"publisher","first-page":"113ra126","DOI":"10.1126\/scitranslmed.3002669","volume":"3","author":"AL Wu","year":"2011","unstructured":"Wu, A. L. et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci. Transl. Med. 3, 113ra126 (2011).","journal-title":"Sci. Transl. Med."},{"key":"1125_CR158","doi-asserted-by":"publisher","first-page":"14678","DOI":"10.1074\/jbc.RA118.004343","volume":"293","author":"X Min","year":"2018","unstructured":"Min, X. et al. Agonistic \u03b2-Klotho antibody mimics fibroblast growth factor 21 (FGF21) functions. J. Biol. Chem. 293, 14678\u201314688 (2018).","journal-title":"J. Biol. Chem."},{"key":"1125_CR159","doi-asserted-by":"publisher","first-page":"162ra153","DOI":"10.1126\/scitranslmed.3004690","volume":"4","author":"IN Foltz","year":"2012","unstructured":"Foltz, I. N. et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the \u03b2Klotho\/FGFR1c receptor complex. Sci. Transl. Med. 4, 162ra153 (2012).","journal-title":"Sci. Transl. Med."},{"key":"1125_CR160","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.ebiom.2015.05.028","volume":"2","author":"G Kolumam","year":"2015","unstructured":"Kolumam, G. et al. Sustained brown fat stimulation and insulin sensitization by a humanized bispecific antibody agonist for fibroblast growth factor receptor 1\/\u03b2Klotho complex. EBioMedicine 2, 730\u2013743 (2015).","journal-title":"EBioMedicine"},{"key":"1125_CR161","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/psp4.13111","volume":"13","author":"K Yoshida","year":"2024","unstructured":"Yoshida, K. et al. Simulation-based evaluation of personalized dosing approaches for anti-FGFR\/KLB bispecific antibody fazpilodemab. CPT Pharmacomet. Syst. Pharmacol. 13, 544\u2013550 (2024).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"1125_CR162","doi-asserted-by":"publisher","first-page":"140-LB","DOI":"10.2337\/db19-140-LB","volume":"68","author":"A DePaoli","year":"2019","unstructured":"DePaoli, A. et al. 140-LB: NGM313, a novel activator of b-Klotho\/FGFR1c, improves insulin resistance and reduces hepatic fat in obese, nondiabetic subjects. Diabetes 68, 140-LB (2019).","journal-title":"Diabetes"},{"key":"1125_CR163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061432","volume":"8","author":"R Smith","year":"2013","unstructured":"Smith, R. et al. FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c\/\u03b2-Klotho bispecific protein. PLoS ONE 8, e61432 (2013).","journal-title":"PLoS ONE"},{"key":"1125_CR164","doi-asserted-by":"publisher","first-page":"175811","DOI":"10.1016\/j.ejphar.2023.175811","volume":"952","author":"X Ye","year":"2023","unstructured":"Ye, X. et al. Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis. Eur. J. Pharmacol. 952, 175811 (2023).","journal-title":"Eur. J. Pharmacol."},{"key":"1125_CR165","doi-asserted-by":"publisher","first-page":"103202","DOI":"10.1016\/j.ebiom.2020.103202","volume":"63","author":"Q Pan","year":"2021","unstructured":"Pan, Q. et al. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine 63, 103202 (2021).","journal-title":"EBioMedicine"},{"key":"1125_CR166","doi-asserted-by":"publisher","DOI":"10.5812\/ijpr-131015","volume":"22","author":"C Zhang","year":"2023","unstructured":"Zhang, C. et al. Design of a dual agonist of exendin-4 and FGF21 as a potential treatment for type 2 diabetes mellitus and obesity. Iran. J. Pharm. Res. 22, e131015 (2023).","journal-title":"Iran. J. Pharm. Res."},{"key":"1125_CR167","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1002\/hep.32028","volume":"74","author":"V Meadows","year":"2021","unstructured":"Meadows, V. et al. Mast cells regulate ductular reaction and intestinal inflammation in cholestasis through farnesoid X receptor signaling. Hepatology 74, 2684\u20132698 (2021).","journal-title":"Hepatology"},{"key":"1125_CR168","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1002\/hep.32017","volume":"74","author":"KVK Koelfat","year":"2021","unstructured":"Koelfat, K. V. K. et al. Chyme reinfusion restores the regulatory bile salt-FGF19 axis in patients with intestinal failure. Hepatology 74, 2670\u20132683 (2021).","journal-title":"Hepatology"},{"key":"1125_CR169","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04697-5","volume":"9","author":"S Byun","year":"2018","unstructured":"Byun, S. et al. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis. Nat. Commun. 9, 2590 (2018).","journal-title":"Nat. Commun."},{"key":"1125_CR170","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.gastro.2015.05.043","volume":"149","author":"WE Naugler","year":"2015","unstructured":"Naugler, W. E. et al. Fibroblast growth factor signaling controls liver size in mice with humanized livers. Gastroenterology 149, 728\u2013740.e715 (2015).","journal-title":"Gastroenterology"},{"key":"1125_CR171","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17363-6","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. An FGF15\/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis. Nat. Commun. 11, 3612 (2020).","journal-title":"Nat. Commun."},{"key":"1125_CR172","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jhep.2018.03.031","volume":"69","author":"K Brandl","year":"2018","unstructured":"Brandl, K. et al. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J. Hepatol. 69, 396\u2013405 (2018).","journal-title":"J. Hepatol."},{"key":"1125_CR173","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hep.28257","volume":"63","author":"M Zhou","year":"2016","unstructured":"Zhou, M. et al. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology 63, 914\u2013929 (2016).","journal-title":"Hepatology"},{"key":"1125_CR174","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","volume":"13","author":"MJ Potthoff","year":"2011","unstructured":"Potthoff, M. J. et al. FGF15\/19 regulates hepatic glucose metabolism by inhibiting the CREB\u2013PGC-1\u03b1 pathway. Cell Metab. 13, 729\u2013738 (2011).","journal-title":"Cell Metab."},{"key":"1125_CR175","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1101\/gad.184788.111","volume":"26","author":"MJ Potthoff","year":"2012","unstructured":"Potthoff, M. J., Kliewer, S. A. & Mangelsdorf, D. J. Endocrine fibroblast growth factors 15\/19 and 21: from feast to famine. Genes Dev. 26, 312\u2013324 (2012).","journal-title":"Genes Dev."},{"key":"1125_CR176","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.1198363","volume":"331","author":"S Kir","year":"2011","unstructured":"Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621\u20131624 (2011).","journal-title":"Science"},{"key":"1125_CR177","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molmet.2013.10.002","volume":"3","author":"G Marcelin","year":"2014","unstructured":"Marcelin, G. et al. Central action of FGF19 reduces hypothalamic AGRP\/NPY neuron activity and improves glucose metabolism. Mol. Metab. 3, 19\u201328 (2014).","journal-title":"Mol. Metab."},{"key":"1125_CR178","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1172\/JCI70710","volume":"123","author":"GJ Morton","year":"2013","unstructured":"Morton, G. J. et al. FGF19 action in the brain induces insulin-independent glucose lowering. J. Clin. Invest. 123, 4799\u20134808 (2013).","journal-title":"J. Clin. Invest."},{"key":"1125_CR179","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1210\/en.2012-1891","volume":"154","author":"KK Ryan","year":"2013","unstructured":"Ryan, K. K. et al. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 154, 9\u201315 (2013).","journal-title":"Endocrinology"},{"key":"1125_CR180","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cmet.2017.09.005","volume":"26","author":"T Lan","year":"2017","unstructured":"Lan, T. et al. FGF19, FGF21, and an FGFR1\/\u03b2-Klotho-activating antibody act on the nervous system to regulate body weight and glycemia. Cell Metab. 26, 709\u2013718.e703 (2017).","journal-title":"Cell Metab."},{"key":"1125_CR181","doi-asserted-by":"publisher","first-page":"101483","DOI":"10.1016\/j.molmet.2022.101483","volume":"60","author":"J Ursic-Bedoya","year":"2022","unstructured":"Ursic-Bedoya, J. et al. Fibroblast growth factor 19 stimulates water intake. Mol. Metab. 60, 101483 (2022).","journal-title":"Mol. Metab."},{"key":"1125_CR182","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13578-023-00955-2","volume":"13","author":"A Huang","year":"2023","unstructured":"Huang, A., Maier, M. T., Vagena, E. & Xu, A. W. Modulation of foraging-like behaviors by cholesterol-FGF19 axis. Cell Biosci. 13, 20 (2023).","journal-title":"Cell Biosci."},{"key":"1125_CR183","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molmet.2019.09.006","volume":"30","author":"PJ Antonellis","year":"2019","unstructured":"Antonellis, P. J. et al. The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis. Mol. Metab. 30, 131\u2013139 (2019).","journal-title":"Mol. Metab."},{"key":"1125_CR184","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021109997","volume":"41","author":"S Seok","year":"2022","unstructured":"Seok, S. et al. Feeding activates FGF15\u2013SHP\u2013TFEB-mediated lipophagy in the gut. EMBO J. 41, e109997 (2022).","journal-title":"EMBO J."},{"key":"1125_CR185","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1053\/j.gastro.2018.11.061","volume":"156","author":"YC Kim","year":"2019","unstructured":"Kim, Y. C. et al. Small heterodimer partner and fibroblast growth factor 19 inhibit expression of NPC1L1 in mouse intestine and cholesterol absorption. Gastroenterology 156, 1052\u20131065 (2019).","journal-title":"Gastroenterology"},{"key":"1125_CR186","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.15252\/embj.201695500","volume":"36","author":"S Byun","year":"2017","unstructured":"Byun, S. et al. A postprandial FGF19\u2013SHP\u2013LSD1 regulatory axis mediates epigenetic repression of hepatic autophagy. EMBO J. 36, 1755\u20131769 (2017).","journal-title":"EMBO J."},{"key":"1125_CR187","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19803-9","volume":"11","author":"YC Kim","year":"2020","unstructured":"Kim, Y. C. et al. Intestinal FGF15\/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A. Nat. Commun. 11, 5969 (2020).","journal-title":"Nat. Commun."},{"key":"1125_CR188","doi-asserted-by":"publisher","first-page":"8732","DOI":"10.1074\/jbc.RA119.008360","volume":"294","author":"S Byun","year":"2019","unstructured":"Byun, S. et al. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis. J. Biol. Chem. 294, 8732\u20138744 (2019).","journal-title":"J. Biol. Chem."},{"key":"1125_CR189","doi-asserted-by":"publisher","first-page":"101113","DOI":"10.1016\/j.molmet.2020.101113","volume":"43","author":"S Mor\u00f3n-Ros","year":"2021","unstructured":"Mor\u00f3n-Ros, S. et al. FGF15\/19 is required for adipose tissue plasticity in response to thermogenic adaptations. Mol. Metab. 43, 101113 (2021).","journal-title":"Mol. Metab."},{"key":"1125_CR190","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/nm.4363","volume":"23","author":"B Benoit","year":"2017","unstructured":"Benoit, B. et al. Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice. Nat. Med. 23, 990\u2013996 (2017).","journal-title":"Nat. Med."},{"key":"1125_CR191","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1111\/jcmm.16448","volume":"25","author":"A Guo","year":"2021","unstructured":"Guo, A. et al. FGF19 protects skeletal muscle against obesity-induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK\/SIRT-1\/PGC-\u03b1 pathway. J. Cell Mol. Med. 25, 3585\u20133600 (2021).","journal-title":"J. Cell Mol. Med."},{"key":"1125_CR192","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/jcsm.12819","volume":"12","author":"SDC Pereira","year":"2021","unstructured":"Pereira, S. D. C. et al. Fibroblast growth factor 19 as a countermeasure to muscle and locomotion dysfunctions in experimental cerebral palsy. J. Cachexia Sarcopenia Muscle 12, 2122\u20132133 (2021).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1125_CR193","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","volume":"9","author":"RD Kim","year":"2019","unstructured":"Kim, R. D. et al. First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 9, 1696\u20131707 (2019).","journal-title":"Cancer Discov."},{"key":"1125_CR194","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1038\/s41388-020-1227-2","volume":"39","author":"F Li","year":"2020","unstructured":"Li, F. et al. Enhanced autocrine FGF19\/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104. Oncogene 39, 3507\u20133521 (2020).","journal-title":"Oncogene"},{"key":"1125_CR195","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1172\/JCI41514","volume":"121","author":"H Wang","year":"2011","unstructured":"Wang, H. et al. Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J. Clin. Invest. 121, 3220\u20133232 (2011).","journal-title":"J. Clin. Invest."},{"key":"1125_CR196","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151601","volume":"133","author":"L Chia","year":"2023","unstructured":"Chia, L. et al. HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation. J. Clin. Invest. 133, e151601 (2023).","journal-title":"J. Clin. Invest."},{"key":"1125_CR197","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1038\/s41388-021-01850-1","volume":"40","author":"T Chen","year":"2021","unstructured":"Chen, T. et al. FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1\u2013cAMP\u2013EGR1 axis. Oncogene 40, 4941\u20134953 (2021).","journal-title":"Oncogene"},{"key":"1125_CR198","doi-asserted-by":"publisher","first-page":"14158","DOI":"10.1073\/pnas.1009427107","volume":"107","author":"X Wu","year":"2010","unstructured":"Wu, X. et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc. Natl Acad. Sci. USA 107, 14158\u201314163 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR199","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","volume":"19","author":"ET Sawey","year":"2011","unstructured":"Sawey, E. T. et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19, 347\u2013358 (2011).","journal-title":"Cancer Cell"},{"key":"1125_CR200","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017868","volume":"6","author":"AL Wu","year":"2011","unstructured":"Wu, A. L. et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS ONE 6, e17868 (2011).","journal-title":"PLoS ONE"},{"key":"1125_CR201","doi-asserted-by":"publisher","first-page":"247ra100","DOI":"10.1126\/scitranslmed.3009098","volume":"6","author":"J Luo","year":"2014","unstructured":"Luo, J. et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci. Transl. Med. 6, 247ra100 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1125_CR202","doi-asserted-by":"publisher","first-page":"29025","DOI":"10.1073\/pnas.2010984117","volume":"117","author":"J Niu","year":"2020","unstructured":"Niu, J. et al. Curtailing FGF19\u2019s mitogenicity by suppressing its receptor dimerization ability. Proc. Natl Acad. Sci. USA 117, 29025\u201329034 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR203","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","volume":"7","author":"SA Harrison","year":"2022","unstructured":"Harrison, S. A. et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol. Hepatol. 7, 603\u2013616 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1125_CR204","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","volume":"79","author":"ME Rinella","year":"2024","unstructured":"Rinella, M. E. et al. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology 79, 674\u2013689 (2024).","journal-title":"Hepatology"},{"key":"1125_CR205","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/hep4.1209","volume":"2","author":"MJ Mayo","year":"2018","unstructured":"Mayo, M. J. et al. NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. Hepatol. Commun. 2, 1037\u20131050 (2018).","journal-title":"Hepatol. Commun."},{"key":"1125_CR206","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","volume":"391","author":"SA Harrison","year":"2018","unstructured":"Harrison, S. A. et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 391, 1174\u20131185 (2018).","journal-title":"Lancet"},{"key":"1125_CR207","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41395-018-0042-7","volume":"113","author":"I Oduyebo","year":"2018","unstructured":"Oduyebo, I. et al. Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial. Am. J. Gastroenterol. 113, 725\u2013734 (2018).","journal-title":"Am. J. Gastroenterol."},{"key":"1125_CR208","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1194\/jlr.M089961","volume":"60","author":"M Zhou","year":"2019","unstructured":"Zhou, M. et al. Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis. J. Lipid Res. 60, 550\u2013565 (2019).","journal-title":"J. Lipid Res."},{"key":"1125_CR209","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","volume":"70","author":"GM Hirschfield","year":"2019","unstructured":"Hirschfield, G. M. et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. J. Hepatol. 70, 483\u2013493 (2019).","journal-title":"J. Hepatol."},{"key":"1125_CR210","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jhep.2018.11.032","volume":"70","author":"ME Rinella","year":"2019","unstructured":"Rinella, M. E. et al. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J. Hepatol. 70, 735\u2013744 (2019).","journal-title":"J. Hepatol."},{"key":"1125_CR211","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s44321-023-00021-x","volume":"16","author":"J Ursic-Bedoya","year":"2024","unstructured":"Ursic-Bedoya, J. et al. FGF19 and its analog aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis. EMBO Mol. Med. 16, 238\u2013250 (2024).","journal-title":"EMBO Mol. Med."},{"key":"1125_CR212","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","volume":"16","author":"D Edmonston","year":"2020","unstructured":"Edmonston, D. & Wolf, M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat. Rev. Nephrol. 16, 7\u201319 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"1125_CR213","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1073\/pnas.1402218111","volume":"111","author":"VS Tagliabracci","year":"2014","unstructured":"Tagliabracci, V. S. et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc. Natl Acad. Sci. USA 111, 5520\u20135525 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR214","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41589-019-0444-x","volume":"16","author":"M de Las Rivas","year":"2020","unstructured":"de Las Rivas, M. et al. Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3. Nat. Chem. Biol. 16, 351\u2013360 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"1125_CR215","doi-asserted-by":"publisher","first-page":"31800","DOI":"10.1073\/pnas.2018554117","volume":"117","author":"Y Suzuki","year":"2020","unstructured":"Suzuki, Y. et al. FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with \u03b1-Klotho. Proc. Natl Acad. Sci. USA 117, 31800\u201331807 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR216","doi-asserted-by":"publisher","first-page":"108665","DOI":"10.1016\/j.celrep.2020.108665","volume":"34","author":"A Agrawal","year":"2021","unstructured":"Agrawal, A., Ni, P., Agoro, R., White, K. E. & DiMarchi, R. D. Identification of a second Klotho interaction site in the C terminus of FGF23. Cell Rep. 34, 108665 (2021).","journal-title":"Cell Rep."},{"key":"1125_CR217","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajhg.2010.01.006","volume":"86","author":"B Lorenz-Depiereux","year":"2010","unstructured":"Lorenz-Depiereux, B., Schnabel, D., Tiosano, D., H\u00e4usler, G. & Strom, T. M. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am. J. Hum. Genet. 86, 267\u2013272 (2010).","journal-title":"Am. J. Hum. Genet."},{"key":"1125_CR218","doi-asserted-by":"publisher","first-page":"1008800","DOI":"10.3389\/fendo.2022.1008800","volume":"13","author":"Q Zuo","year":"2022","unstructured":"Zuo, Q. et al. A novel FGF23 mutation in hyperphosphatemic familial tumoral calcinosis and its deleterious effect on protein O-glycosylation. Front. Endocrinol. 13, 1008800 (2022).","journal-title":"Front. Endocrinol."},{"key":"1125_CR219","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.gene.2014.03.052","volume":"542","author":"F Abbasi","year":"2014","unstructured":"Abbasi, F. et al. A new missense mutation in FGF23 gene in a male with hyperostosis-hyperphosphatemia syndrome (HHS). Gene 542, 269\u2013271 (2014).","journal-title":"Gene"},{"key":"1125_CR220","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1172\/JCI122004","volume":"128","author":"MS Roberts","year":"2018","unstructured":"Roberts, M. S. et al. Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies. J. Clin. Invest. 128, 5368\u20135373 (2018).","journal-title":"J. Clin. Invest."},{"key":"1125_CR221","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez, O. M. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359, 584\u2013592 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR222","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova, T. et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305, 2432\u20132439 (2011).","journal-title":"JAMA"},{"key":"1125_CR223","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.kint.2016.12.029","volume":"91","author":"FG Graciolli","year":"2017","unstructured":"Graciolli, F. G. et al. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Kidney Int. 91, 1436\u20131446 (2017).","journal-title":"Kidney Int."},{"key":"1125_CR224","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-physiol-021119-034650","volume":"82","author":"J Musgrove","year":"2020","unstructured":"Musgrove, J. & Wolf, M. Regulation and effects of FGF23 in chronic kidney disease. Annu. Rev. Physiol. 82, 365\u2013390 (2020).","journal-title":"Annu. Rev. Physiol."},{"key":"1125_CR225","doi-asserted-by":"publisher","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","volume":"299","author":"V Lavi-Moshayoff","year":"2010","unstructured":"Lavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J. & Naveh-Many, T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am. J. Physiol. Ren. Physiol. 299, F882\u2013889 (2010).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"1125_CR226","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1172\/JCI29463","volume":"116","author":"R Masuyama","year":"2006","unstructured":"Masuyama, R. et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J. Clin. Invest. 116, 3150\u20133159 (2006).","journal-title":"J. Clin. Invest."},{"key":"1125_CR227","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/ki.2013.198","volume":"84","author":"M Christov","year":"2013","unstructured":"Christov, M. & J\u00fcppner, H. Dietary phosphate: the challenges of exploring its role in FGF23 regulation. Kidney Int. 84, 639\u2013641 (2013).","journal-title":"Kidney Int."},{"key":"1125_CR228","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1681\/ASN.2019111172","volume":"31","author":"P Florenzano","year":"2020","unstructured":"Florenzano, P. et al. Nephropathic cystinosis: a distinct form of CKD-mineral and bone disorder that provides novel insights into the regulation of FGF23. J. Am. Soc. Nephrol. 31, 2184\u20132192 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1125_CR229","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00109-015-1370-3","volume":"94","author":"B Zhang","year":"2016","unstructured":"Zhang, B. et al. NF\u03baB-sensitive Orai1 expression in the regulation of FGF23 release. J. Mol. Med. 94, 557\u2013566 (2016).","journal-title":"J. Mol. Med."},{"key":"1125_CR230","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/ki.2015.290","volume":"89","author":"V David","year":"2016","unstructured":"David, V. et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 89, 135\u2013146 (2016).","journal-title":"Kidney Int."},{"key":"1125_CR231","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/boneres.2016.11","volume":"4","author":"Q Zhang","year":"2016","unstructured":"Zhang, Q. et al. The hypoxia-inducible factor-1\u03b1 activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia. Bone Res. 4, 16011 (2016).","journal-title":"Bone Res."},{"key":"1125_CR232","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41413-022-00241-w","volume":"11","author":"ML Noonan","year":"2023","unstructured":"Noonan, M. L. et al. Osteocyte Egln1\/Phd2 links oxygen sensing and biomineralization via FGF23. Bone Res. 11, 7 (2023).","journal-title":"Bone Res."},{"key":"1125_CR233","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/jbmr.4003","volume":"35","author":"Q McKnight","year":"2020","unstructured":"McKnight, Q. et al. IL-1\u03b2 drives production of FGF-23 at the onset of chronic kidney disease in mice. J. Bone Min. Res. 35, 1352\u20131362 (2020).","journal-title":"J. Bone Min. Res."},{"key":"1125_CR234","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.kint.2019.04.009","volume":"96","author":"D Egli-Spichtig","year":"2019","unstructured":"Egli-Spichtig, D. et al. Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation. Kidney Int. 96, 890\u2013905 (2019).","journal-title":"Kidney Int."},{"key":"1125_CR235","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41413-021-00154-0","volume":"9","author":"G Courbon","year":"2021","unstructured":"Courbon, G. et al. Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease. Bone Res. 9, 35 (2021).","journal-title":"Bone Res."},{"key":"1125_CR236","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1172\/JCI131190","volume":"130","author":"P Simic","year":"2020","unstructured":"Simic, P. et al. Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. J. Clin. Invest. 130, 1513\u20131526 (2020).","journal-title":"J. Clin. Invest."},{"key":"1125_CR237","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul, C. et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393\u20134408 (2011).","journal-title":"J. Clin. Invest."},{"key":"1125_CR238","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.113.005499","volume":"130","author":"JS Mathew","year":"2014","unstructured":"Mathew, J. S. et al. Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation 130, 298\u2013307 (2014).","journal-title":"Circulation"},{"key":"1125_CR239","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.kint.2018.02.018","volume":"94","author":"I Matsui","year":"2018","unstructured":"Matsui, I. et al. Cardiac hypertrophy elevates serum levels of fibroblast growth factor 23. Kidney Int. 94, 60\u201371 (2018).","journal-title":"Kidney Int."},{"key":"1125_CR240","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/emmm.201303716","volume":"6","author":"O Andrukhova","year":"2014","unstructured":"Andrukhova, O. et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol. Med. 6, 744\u2013759 (2014).","journal-title":"EMBO Mol. Med."},{"key":"1125_CR241","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bjc.1988.269","volume":"58","author":"FS Steven","year":"1988","unstructured":"Steven, F. S. & Hill, R. J. A study of guanidinobenzoatase during development of mesothelioma induced in the rat by fibrous erionite. Br. J. Cancer 58, 610\u2013613 (1988).","journal-title":"Br. J. Cancer"},{"key":"1125_CR242","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","volume":"22","author":"A Grabner","year":"2015","unstructured":"Grabner, A. et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 22, 1020\u20131032 (2015).","journal-title":"Cell Metab."},{"key":"1125_CR243","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.kint.2022.03.028","volume":"102","author":"C Yanucil","year":"2022","unstructured":"Yanucil, C. et al. Soluble \u03b1-Klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 102, 261\u2013279 (2022).","journal-title":"Kidney Int."},{"key":"1125_CR244","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.kint.2018.02.017","volume":"94","author":"EM Pastor-Arroyo","year":"2018","unstructured":"Pastor-Arroyo, E. M. et al. The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk. Kidney Int. 94, 49\u201359 (2018).","journal-title":"Kidney Int."},{"key":"1125_CR245","doi-asserted-by":"publisher","first-page":"745892","DOI":"10.3389\/fcell.2021.745892","volume":"9","author":"M Leifheit-Nestler","year":"2021","unstructured":"Leifheit-Nestler, M. et al. Cardiac fibroblast growth factor 23 excess does not induce left ventricular hypertrophy in healthy mice. Front. Cell Dev. Biol. 9, 745892 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1125_CR246","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.121.056663","volume":"145","author":"A Henry","year":"2022","unstructured":"Henry, A. et al. Therapeutic targets for heart failure identified using proteomics and mendelian randomization. Circulation 145, 1205\u20131217 (2022).","journal-title":"Circulation"},{"key":"1125_CR247","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1083\/jcb.200803024","volume":"182","author":"D Medici","year":"2008","unstructured":"Medici, D. et al. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J. Cell Biol. 182, 459\u2013465 (2008).","journal-title":"J. Cell Biol."},{"key":"1125_CR248","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0065-230X(08)60305-X","volume":"59","author":"C Basilico","year":"1992","unstructured":"Basilico, C. & Moscatelli, D. The FGF family of growth factors and oncogenes. Adv. Cancer Res. 59, 115\u2013165 (1992).","journal-title":"Adv. Cancer Res."},{"key":"1125_CR249","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s11684-019-0711-y","volume":"13","author":"X Li","year":"2019","unstructured":"Li, X. The FGF metabolic axis. Front. Med. 13, 511\u2013530 (2019).","journal-title":"Front. Med."},{"key":"1125_CR250","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/j.0022-0337.2005.69.8.tb03989.x","volume":"69","author":"SW Redding","year":"2005","unstructured":"Redding, S. W. Cancer therapy-related oral mucositis. J. Dent. Educ. 69, 919\u2013929 (2005).","journal-title":"J. Dent. Educ."},{"key":"1125_CR251","doi-asserted-by":"publisher","first-page":"8318","DOI":"10.1158\/1078-0432.CCR-04-1118","volume":"10","author":"CO Freytes","year":"2004","unstructured":"Freytes, C. O. et al. Phase I\/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clin. Cancer Res. 10, 8318\u20138324 (2004).","journal-title":"Clin. Cancer Res."},{"key":"1125_CR252","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/09553000802007601","volume":"84","author":"G Ara","year":"2008","unstructured":"Ara, G. et al. Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. Int. J. Radiat. Biol. 84, 401\u2013412 (2008).","journal-title":"Int. J. Radiat. Biol."},{"key":"1125_CR253","first-page":"1179","volume":"6","author":"RV Lalla","year":"2005","unstructured":"Lalla, R. V. Velafermin (CuraGen). Curr. Opin. Investig. Drugs 6, 1179\u20131185 (2005).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"1125_CR254","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1046\/j.1365-2036.2003.01589.x","volume":"17","author":"WJ Sandborn","year":"2003","unstructured":"Sandborn, W. J. et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment. Pharmacol. Ther. 17, 1355\u20131364 (2003).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1125_CR255","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1046\/j.1524-475x.2001.00347.x","volume":"9","author":"MC Robson","year":"2001","unstructured":"Robson, M. C. et al. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair. Regen. 9, 347\u2013352 (2001).","journal-title":"Wound Repair. Regen."},{"key":"1125_CR256","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/annrheumdis-2020-219181","volume":"80","author":"F Eckstein","year":"2021","unstructured":"Eckstein, F. et al. Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study. Ann. Rheum. Dis. 80, 1062\u20131069 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1125_CR257","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.semarthrit.2021.03.005","volume":"51","author":"H Guehring","year":"2021","unstructured":"Guehring, H. et al. The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial. Semin. Arthritis Rheum. 51, 450\u2013456 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1125_CR258","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/mt.2008.33","volume":"16","author":"S Nikol","year":"2008","unstructured":"Nikol, S. et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol. Ther. 16, 972\u2013978 (2008).","journal-title":"Mol. Ther."},{"key":"1125_CR259","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(11)60394-2","volume":"377","author":"J Belch","year":"2011","unstructured":"Belch, J. et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 377, 1929\u20131937 (2011).","journal-title":"Lancet"},{"key":"1125_CR260","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S0735-1097(03)00988-4","volume":"42","author":"CL Grines","year":"2003","unstructured":"Grines, C. L. et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J. Am. Coll. Cardiol. 42, 1339\u20131347 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1125_CR261","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1517\/14712598.2013.827656","volume":"13","author":"JC Kaski","year":"2013","unstructured":"Kaski, J. C. & Consuegra-Sanchez, L. Evaluation of ASPIRE trial: a Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris. Expert. Opin. Biol. Ther. 13, 1749\u20131753 (2013).","journal-title":"Expert. Opin. Biol. Ther."},{"key":"1125_CR262","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature13540","volume":"513","author":"JM Suh","year":"2014","unstructured":"Suh, J. M. et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 513, 436\u2013439 (2014).","journal-title":"Nature"},{"key":"1125_CR263","doi-asserted-by":"publisher","first-page":"E822","DOI":"10.1152\/ajpendo.00270.2020","volume":"320","author":"R Moure","year":"2021","unstructured":"Moure, R. et al. Levels of \u03b2-Klotho determine the thermogenic responsiveness of adipose tissues: involvement of the autocrine action of FGF21. Am. J. Physiol. Endocrinol. Metab. 320, E822\u2013e834 (2021).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1125_CR264","doi-asserted-by":"publisher","first-page":"156781","DOI":"10.1016\/j.cyto.2024.156781","volume":"184","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. The FGF23-Klotho axis promotes microinflammation in chronic kidney disease. Cytokine 184, 156781 (2024).","journal-title":"Cytokine"},{"key":"1125_CR265","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/ijo.2014.76","volume":"39","author":"JM Gallego-Escuredo","year":"2015","unstructured":"Gallego-Escuredo, J. M. et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int. J. Obes. 39, 121\u2013129 (2015).","journal-title":"Int. J. Obes."},{"key":"1125_CR266","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16026-w","volume":"11","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. Adipocyte Piezo1 mediates obesogenic adipogenesis through the FGF1\/FGFR1 signaling pathway in mice. Nat. Commun. 11, 2303 (2020).","journal-title":"Nat. Commun."},{"key":"1125_CR267","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122382119","volume":"119","author":"VJM Nies","year":"2022","unstructured":"Nies, V. J. M. et al. Autocrine FGF1 signaling promotes glucose uptake in adipocytes. Proc. Natl Acad. Sci. USA 119, e2122382119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR268","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cmet.2021.12.004","volume":"34","author":"G Sancar","year":"2022","unstructured":"Sancar, G. et al. FGF1 and insulin control lipolysis by convergent pathways. Cell Metab. 34, 171\u2013183.e176 (2022).","journal-title":"Cell Metab."},{"key":"1125_CR269","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27584-y","volume":"12","author":"L Ying","year":"2021","unstructured":"Ying, L. et al. Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects. Nat. Commun. 12, 7256 (2021).","journal-title":"Nat. Commun."},{"key":"1125_CR270","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s42255-020-00275-6","volume":"2","author":"KM Alonge","year":"2020","unstructured":"Alonge, K. M. et al. Hypothalamic perineuronal net assembly is required for sustained diabetes remission induced by fibroblast growth factor 1 in rats. Nat. Metab. 2, 1025\u20131033 (2020).","journal-title":"Nat. Metab."},{"key":"1125_CR271","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17720-5","volume":"11","author":"MA Bentsen","year":"2020","unstructured":"Bentsen, M. A. et al. Transcriptomic analysis links diverse hypothalamic cell types to fibroblast growth factor 1-induced sustained diabetes remission. Nat. Commun. 11, 4458 (2020).","journal-title":"Nat. Commun."},{"key":"1125_CR272","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.2337\/db19-0025","volume":"68","author":"JM Brown","year":"2019","unstructured":"Brown, J. M. et al. The hypothalamic arcuate nucleus-median eminence is a target for sustained diabetes remission induced by fibroblast growth factor 1. Diabetes 68, 1054\u20131061 (2019).","journal-title":"Diabetes"},{"key":"1125_CR273","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2337\/db18-0498","volume":"68","author":"JM Scarlett","year":"2019","unstructured":"Scarlett, J. M. et al. Peripheral mechanisms mediating the sustained antidiabetic action of FGF1 in the brain. Diabetes 68, 654\u2013664 (2019).","journal-title":"Diabetes"},{"key":"1125_CR274","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/db18-1175","volume":"68","author":"KG Tennant","year":"2019","unstructured":"Tennant, K. G., Lindsley, S. R., Kirigiti, M. A., True, C. & Kievit, P. Central and peripheral administration of fibroblast growth factor 1 improves pancreatic islet insulin secretion in diabetic mouse models. Diabetes 68, 1462\u20131472 (2019).","journal-title":"Diabetes"},{"key":"1125_CR275","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1016\/j.xphs.2016.09.005","volume":"105","author":"X Xia","year":"2016","unstructured":"Xia, X. et al. An S116R phosphorylation site mutation in human fibroblast growth factor-1 differentially affects mitogenic and glucose-lowering activities. J. Pharm. Sci. 105, 3507\u20133519 (2016).","journal-title":"J. Pharm. Sci."},{"key":"1125_CR276","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.celrep.2017.06.063","volume":"20","author":"Z Huang","year":"2017","unstructured":"Huang, Z. et al. Uncoupling the mitogenic and metabolic functions of FGF1 by tuning FGF1-FGF receptor dimer stability. Cell Rep. 20, 1717\u20131728 (2017).","journal-title":"Cell Rep."},{"key":"1125_CR277","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41392-021-00542-2","volume":"6","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. FGF1\u0394HBS prevents diabetic cardiomyopathy by maintaining mitochondrial homeostasis and reducing oxidative stress via AMPK\/Nur77 suppression. Signal. Transduct. Target. Ther. 6, 133 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1125_CR278","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ebiom.2019.09.052","volume":"48","author":"L Zhao","year":"2019","unstructured":"Zhao, L. et al. Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases. EBioMedicine 48, 462\u2013477 (2019).","journal-title":"EBioMedicine"},{"key":"1125_CR279","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ebiom.2019.10.019","volume":"49","author":"KH Flippo","year":"2019","unstructured":"Flippo, K. H. & Potthoff, M. J. Chronicles of an FGF chimera: the odyssey continues. EBioMedicine 49, 15\u201316 (2019).","journal-title":"EBioMedicine"},{"key":"1125_CR280","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1073\/pnas.1525093113","volume":"113","author":"W Liu","year":"2016","unstructured":"Liu, W. et al. Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease. Proc. Natl Acad. Sci. USA 113, 2288\u20132293 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR281","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/hep.31568","volume":"73","author":"Q Lin","year":"2021","unstructured":"Lin, Q. et al. Activating adenosine monophosphate-activated protein kinase mediates fibroblast growth factor 1 protection from nonalcoholic fatty liver disease in mice. Hepatology 73, 2206\u20132222 (2021).","journal-title":"Hepatology"},{"key":"1125_CR282","doi-asserted-by":"publisher","first-page":"29134","DOI":"10.1074\/jbc.M112.342980","volume":"287","author":"R Goetz","year":"2012","unstructured":"Goetz, R. et al. Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J. Biol. Chem. 287, 29134\u201329146 (2012).","journal-title":"J. Biol. Chem."},{"key":"1125_CR283","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/hep.32404","volume":"76","author":"L Song","year":"2022","unstructured":"Song, L. et al. FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase\u2013Caspase 6 signal axis. Hepatology 76, 1105\u20131120 (2022).","journal-title":"Hepatology"},{"key":"1125_CR284","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/gcc.22753","volume":"58","author":"M Urbini","year":"2019","unstructured":"Urbini, M. et al. Gain of FGF4 is a frequent event in KIT\/PDGFRA\/SDH\/RAS-P WT GIST. Genes Chromosomes Cancer 58, 636\u2013642 (2019).","journal-title":"Genes Chromosomes Cancer"},{"key":"1125_CR285","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-019-1668-3","volume":"575","author":"WA Flavahan","year":"2019","unstructured":"Flavahan, W. A. et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature 575, 229\u2013233 (2019).","journal-title":"Nature"},{"key":"1125_CR286","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ccr.2014.02.005","volume":"25","author":"Z Cao","year":"2014","unstructured":"Cao, Z. et al. Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance. Cancer Cell 25, 350\u2013365 (2014).","journal-title":"Cancer Cell"},{"key":"1125_CR287","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ccell.2016.11.010","volume":"31","author":"Z Cao","year":"2017","unstructured":"Cao, Z. et al. Molecular checkpoint decisions made by subverted vascular niche transform indolent tumor cells into chemoresistant cancer stem cells. Cancer Cell 31, 110\u2013126 (2017).","journal-title":"Cancer Cell"},{"key":"1125_CR288","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166560","volume":"1868","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. A non-mitogenic FGF4 analog alleviates non-alcoholic steatohepatitis through an AMPK-dependent pathway. Biochim. Biophys. Acta Mol. Basis Dis. 1868, 166560 (2022).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1125_CR289","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2337\/db22-0585","volume":"72","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. Fibroblast growth factor 6 promotes adipocyte progenitor cell proliferation for adipose tissue homeostasis. Diabetes 72, 467\u2013482 (2023).","journal-title":"Diabetes"},{"key":"1125_CR290","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149969","volume":"6","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. Skeletal muscle-targeted delivery of Fgf6 protects mice from diet-induced obesity and insulin resistance. JCI Insight 6, e149969 (2021).","journal-title":"JCI Insight"},{"key":"1125_CR291","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1182\/blood-2018-10-879585","volume":"133","author":"S Guo","year":"2019","unstructured":"Guo, S. et al. A gene-based recessive diplotype exome scan discovers FGF6, a novel hepcidin-regulating iron-metabolism gene. Blood 133, 1888\u20131898 (2019).","journal-title":"Blood"},{"key":"1125_CR292","doi-asserted-by":"publisher","first-page":"850128","DOI":"10.3389\/fphar.2022.850128","volume":"13","author":"F Zhao","year":"2022","unstructured":"Zhao, F. et al. FGF9 alleviates the fatty liver phenotype by regulating hepatic lipid metabolism. Front. Pharmacol. 13, 850128 (2022).","journal-title":"Front. Pharmacol."},{"key":"1125_CR293","doi-asserted-by":"publisher","first-page":"BSR20230677","DOI":"10.1042\/BSR20230677","volume":"43","author":"S Kar","year":"2023","unstructured":"Kar, S. et al. Reprogramming of glucose metabolism via PFKFB4 is critical in FGF16-driven invasion of breast cancer cells. Biosci. Rep. 43, BSR20230677 (2023).","journal-title":"Biosci. Rep."},{"key":"1125_CR294","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.str.2017.06.016","volume":"25","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. Regulation of receptor binding specificity of FGF9 by an autoinhibitory homodimerization. Structure 25, 1325\u20131336.e1323 (2017).","journal-title":"Structure"},{"key":"1125_CR295","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02158-z","volume":"8","author":"C Fischer","year":"2017","unstructured":"Fischer, C. et al. A miR-327\u2013FGF10\u2013FGFR2-mediated autocrine signaling mechanism controls white fat browning. Nat. Commun. 8, 2079 (2017).","journal-title":"Nat. Commun."},{"key":"1125_CR296","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00394-020-02362-6","volume":"60","author":"W Chen","year":"2021","unstructured":"Chen, W. et al. Betaine prevented high-fat diet-induced NAFLD by regulating the FGF10\/AMPK signaling pathway in ApoE\u2212\/\u2212 mice. Eur. J. Nutr. 60, 1655\u20131668 (2021).","journal-title":"Eur. J. Nutr."},{"key":"1125_CR297","doi-asserted-by":"publisher","first-page":"15292","DOI":"10.1074\/jbc.271.25.15292","volume":"271","author":"DM Ornitz","year":"1996","unstructured":"Ornitz, D. M. et al. Receptor specificity of the fibroblast growth factor family. J. Biol. Chem. 271, 15292\u201315297 (1996).","journal-title":"J. Biol. Chem."},{"key":"1125_CR298","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1016\/j.cell.2024.05.025","volume":"187","author":"NI Edman","year":"2024","unstructured":"Edman, N. I. et al. Modulation of FGF pathway signaling and vascular differentiation using designed oligomeric assemblies. Cell 187, 3726\u20133740.e3743 (2024).","journal-title":"Cell"},{"key":"1125_CR299","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bcp.2018.01.029","volume":"150","author":"C Li","year":"2018","unstructured":"Li, C. et al. Glutazumab, a novel long-lasting GLP-1\/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites. Biochem. Pharmacol. 150, 46\u201353 (2018).","journal-title":"Biochem. Pharmacol."},{"key":"1125_CR300","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","volume":"23","author":"N Gong","year":"2024","unstructured":"Gong, N. et al. Enhancing in situ cancer vaccines using delivery technologies. Nat. Rev. Drug. Discov. 23, 607\u2013625 (2024).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1125_CR301","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1021\/acschembio.7b00218","volume":"12","author":"EL Schneider","year":"2017","unstructured":"Schneider, E. L. et al. A hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist. ACS Chem. Biol. 12, 2107\u20132116 (2017).","journal-title":"ACS Chem. Biol."},{"key":"1125_CR302","doi-asserted-by":"publisher","first-page":"2160518","DOI":"10.1080\/10717544.2022.2160518","volume":"30","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease. Drug. Deliv. 30, 2160518 (2023).","journal-title":"Drug. Deliv."},{"key":"1125_CR303","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","volume":"7","author":"E Nance","year":"2022","unstructured":"Nance, E., Pun, S. H., Saigal, R. & Sellers, D. L. Drug delivery to the central nervous system. Nat. Rev. Mater. 7, 314\u2013331 (2022).","journal-title":"Nat. Rev. Mater."},{"key":"1125_CR304","doi-asserted-by":"publisher","first-page":"eabb4429","DOI":"10.1126\/sciadv.abb4429","volume":"6","author":"F Ma","year":"2020","unstructured":"Ma, F. et al. Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection. Sci. Adv. 6, eabb4429 (2020).","journal-title":"Sci. Adv."},{"key":"1125_CR305","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","volume":"25","author":"D Goertsen","year":"2022","unstructured":"Goertsen, D. et al. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat. Neurosci. 25, 106\u2013115 (2022).","journal-title":"Nat. Neurosci."},{"key":"1125_CR306","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41551-022-00938-7","volume":"6","author":"Y Yao","year":"2022","unstructured":"Yao, Y. et al. Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood-brain barrier in rodents and primates. Nat. Biomed. Eng. 6, 1257\u20131271 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"1125_CR307","doi-asserted-by":"publisher","first-page":"eabd6889","DOI":"10.1126\/sciadv.abd6889","volume":"7","author":"W Li","year":"2021","unstructured":"Li, W. et al. BBB pathophysiology-independent delivery of siRNA in traumatic brain injury. Sci. Adv. 7, eabd6889 (2021).","journal-title":"Sci. Adv."},{"key":"1125_CR308","doi-asserted-by":"publisher","first-page":"104277","DOI":"10.1016\/j.ebiom.2022.104277","volume":"84","author":"D Ye","year":"2022","unstructured":"Ye, D. et al. Incisionless targeted adeno-associated viral vector delivery to the brain by focused ultrasound-mediated intranasal administration. EBioMedicine 84, 104277 (2022).","journal-title":"EBioMedicine"},{"key":"1125_CR309","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1042\/BCJ20180555","volume":"475","author":"AMK Hansen","year":"2018","unstructured":"Hansen, A. M. K. et al. Differential receptor selectivity of the FGF15\/FGF19 orthologues determines distinct metabolic activities in db\/db mice. Biochem. J. 475, 2985\u20132996 (2018).","journal-title":"Biochem. J."},{"key":"1125_CR310","first-page":"4750","volume":"8","author":"JH Lee","year":"2016","unstructured":"Lee, J. H. et al. An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function. Am. J. Transl. Res. 8, 4750\u20134763 (2016).","journal-title":"Am. J. Transl. Res."},{"key":"1125_CR311","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejphar.2013.06.023","volume":"715","author":"RC Camacho","year":"2013","unstructured":"Camacho, R. C., Zafian, P. T., Achanfuo-Yeboah, J., Manibusan, A. & Berger, J. P. Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice. Eur. J. Pharmacol. 715, 41\u201345 (2013).","journal-title":"Eur. J. Pharmacol."},{"key":"1125_CR312","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","volume":"29","author":"DL Bhatt","year":"2023","unstructured":"Bhatt, D. L. et al. The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nat. Med. 29, 1782\u20131792 (2023).","journal-title":"Nat. Med."},{"key":"1125_CR313","doi-asserted-by":"publisher","first-page":"100661","DOI":"10.1016\/j.jhepr.2022.100661","volume":"5","author":"EA Brown","year":"2023","unstructured":"Brown, E. A. et al. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. JHEP Rep. 5, 100661 (2023).","journal-title":"JHEP Rep."},{"key":"1125_CR314","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","volume":"27","author":"SA Harrison","year":"2021","unstructured":"Harrison, S. A. et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat. Med. 27, 1262\u20131271 (2021).","journal-title":"Nat. Med."},{"key":"1125_CR315","doi-asserted-by":"publisher","first-page":"100563","DOI":"10.1016\/j.jhepr.2022.100563","volume":"5","author":"SA Harrison","year":"2023","unstructured":"Harrison, S. A. et al. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Rep. 5, 100563 (2023).","journal-title":"JHEP Rep."},{"key":"1125_CR316","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/dom.13023","volume":"19","author":"AM Kim","year":"2017","unstructured":"Kim, A. M. et al. Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates. Diabetes Obes. Metab. 19, 1762\u20131772 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"1125_CR317","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.molmet.2017.09.003","volume":"6","author":"MZ Chen","year":"2017","unstructured":"Chen, M. Z. et al. FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1\/\u03b2Klotho complex in non-adipocytes. Mol. Metab. 6, 1454\u20131467 (2017).","journal-title":"Mol. Metab."},{"key":"1125_CR318","doi-asserted-by":"publisher","first-page":"28992","DOI":"10.1073\/pnas.2012073117","volume":"117","author":"A Baruch","year":"2020","unstructured":"Baruch, A. et al. Antibody-mediated activation of the FGFR1\/Klotho\u03b2 complex corrects metabolic dysfunction and alters food preference in obese humans. Proc. Natl Acad. Sci. USA 117, 28992\u201329000 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR319","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1136\/gutjnl-2016-312975","volume":"66","author":"G Alvarez-Sola","year":"2017","unstructured":"Alvarez-Sola, G. et al. Fibroblast growth factor 15\/19 (FGF15\/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration. Gut 66, 1818\u20131828 (2017).","journal-title":"Gut"},{"key":"1125_CR320","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1073\/pnas.0902006107","volume":"107","author":"R Goetz","year":"2010","unstructured":"Goetz, R. et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23\u2013FGFR\u2013Klotho complex formation. Proc. Natl Acad. Sci. USA 107, 407\u2013412 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR321","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1002\/jbmr.3197","volume":"32","author":"K Johnson","year":"2017","unstructured":"Johnson, K. et al. Therapeutic effects of FGF23 c-tail Fc in a murine preclinical model of X-linked hypophosphatemia via the selective modulation of phosphate reabsorption. J. Bone Min. Res. 32, 2062\u20132073 (2017).","journal-title":"J. Bone Min. Res."},{"key":"1125_CR322","doi-asserted-by":"publisher","first-page":"eabq3679","DOI":"10.1126\/scitranslmed.abq3679","volume":"15","author":"A Aprile","year":"2023","unstructured":"Aprile, A. et al. Inhibition of FGF23 is a therapeutic strategy to target hematopoietic stem cell niche defects in \u03b2-thalassemia. Sci. Transl. Med. 15, eabq3679 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1125_CR323","doi-asserted-by":"publisher","first-page":"eabj5018","DOI":"10.1126\/sciadv.abj5018","volume":"7","author":"VV Zhukouskaya","year":"2021","unstructured":"Zhukouskaya, V. V. et al. A novel therapeutic strategy for skeletal disorders: proof of concept of gene therapy for X-linked hypophosphatemia. Sci. Adv. 7, eabj5018 (2021).","journal-title":"Sci. Adv."},{"key":"1125_CR324","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel, E. A. et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393, 2416\u20132427 (2019).","journal-title":"Lancet"},{"key":"1125_CR325","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter, T. O. et al. Burosumab therapy in children with X-linked hypophosphatemia. N. Engl. J. Med. 378, 1987\u20131998 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR326","doi-asserted-by":"publisher","first-page":"116598","DOI":"10.1016\/j.bone.2022.116598","volume":"166","author":"J Sugarman","year":"2023","unstructured":"Sugarman, J. et al. The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome. Bone 166, 116598 (2023).","journal-title":"Bone"},{"key":"1125_CR327","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","volume":"36","author":"SM Jan de Beur","year":"2021","unstructured":"Jan de Beur, S. M. et al. Burosumab for the treatment of tumor-induced osteomalacia. J. Bone Min. Res. 36, 627\u2013635 (2021).","journal-title":"J. Bone Min. Res."},{"key":"1125_CR328","doi-asserted-by":"publisher","first-page":"ra113","DOI":"10.1126\/scisignal.aaf5034","volume":"9","author":"Z Xiao","year":"2016","unstructured":"Xiao, Z. et al. A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia. Sci. Signal. 9, ra113 (2016).","journal-title":"Sci. Signal."},{"key":"1125_CR329","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1021\/acs.jcim.2c00633","volume":"62","author":"SH Liu","year":"2022","unstructured":"Liu, S. H. et al. Identification of small-molecule inhibitors of fibroblast growth factor 23 signaling via in silico hot spot prediction and molecular docking to \u03b1-Klotho. J. Chem. Inf. Model. 62, 3627\u20133637 (2022).","journal-title":"J. Chem. Inf. Model."},{"key":"1125_CR330","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1124\/molpharm.121.000471","volume":"101","author":"Z Xiao","year":"2021","unstructured":"Xiao, Z. et al. Novel small molecule fibroblast growth factor 23 inhibitors increase serum phosphate and improve skeletal abnormalities in Hyp mice. Mol. Pharmacol. 101, 408\u2013421 (2021).","journal-title":"Mol. Pharmacol."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-024-01125-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-024-01125-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-024-01125-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:02:14Z","timestamp":1746604934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-024-01125-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":330,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1038\/s41573-024-01125-w","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"19 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}